Dyadic International (DYAI) Other Non-Current Assets (2017 - 2026)
Dyadic International (DYAI) posted Other Non-Current Assets of $908459.0 for Q1 2026, up 8521.61% sequentially from $10537.0 in Q4 2025, and up 8604.22% YoY from $10437.0 in Q1 2025.
Dyadic International (DYAI) Other Non-Current Assets (2017 - 2026) Analysis & Trends
Dyadic International has reported Other Non-Current Assets for 10 years, with the latest figure at $908459.0 in Q1 2026.
- Quarterly Other Non-Current Assets rose 8604.22% year-over-year to $908459.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $908459.0 (up 8604.22% YoY) and the FY2025 annual result came in at $10537.0, up 1.36% from the prior year.
- Other Non-Current Assets climbed to $908459.0 in Q1 2026 per DYAI's latest filing, from $10537.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $6.1 million in Q1 2022 and troughed at $5822.0 in Q2 2023.
- A 5-year average of $434453.2 and a median of $10435.0 in 2024 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets jumped 99135.9% in 2022, then tumbled 99.9% in 2023.
- Over 5 years, Other Non-Current Assets stood at $6045.0 in 2022, then soared by 73.07% to $10462.0 in 2023, then slipped by 0.63% to $10396.0 in 2024, then increased by 1.36% to $10537.0 in 2025, then surged by 8521.61% to $908459.0 in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $908459.0, $10537.0, and $10533.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Dyadic International | 19.98 Mn | 19.98 Mn | - | 908,459.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 908,459.00 |
| Dec 31, 2025 | 10,537.00 |
| Sep 30, 2025 | 10,533.00 |
| Jun 30, 2025 | 245,147.00 |
| Mar 31, 2025 | 10,437.00 |
| Dec 31, 2024 | 10,396.00 |
| Sep 30, 2024 | 10,328.00 |
| Jun 30, 2024 | 10,425.00 |
| Mar 31, 2024 | 10,435.00 |
| Dec 31, 2023 | 10,462.00 |
| Sep 30, 2023 | 14,586.00 |
| Jun 30, 2023 | 5,822.00 |
| Mar 31, 2023 | 6,065.00 |
| Dec 31, 2022 | 6,045.00 |
| Sep 30, 2022 | 6,003.00 |
| Jun 30, 2022 | 6,024.00 |
| Mar 31, 2022 | 6.10 Mn |
| Dec 31, 2021 | 6,117.00 |
| Sep 30, 2021 | 6,143.00 |
| Jun 30, 2021 | 6,172.00 |